Edwards Lifesciences Total Liabilities 2010-2023 | EW

Edwards Lifesciences total liabilities from 2010 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Edwards Lifesciences total liabilities for the quarter ending March 31, 2023 were $2.589B, a 0.55% increase year-over-year.
  • Edwards Lifesciences total liabilities for 2022 were $2.486B, a 6.78% decline from 2021.
  • Edwards Lifesciences total liabilities for 2021 were $2.667B, a 0.15% increase from 2020.
  • Edwards Lifesciences total liabilities for 2020 were $2.663B, a 13.8% increase from 2019.
Edwards Lifesciences Annual Total Liabilities
(Millions of US $)
2022 $2,486
2021 $2,667
2020 $2,663
2019 $2,340
2018 $2,183
2017 $2,710
2016 $1,891
2015 $1,553
2014 $1,332
2013 $1,166
2012 $742
2011 $643
2010 $459
2009 $458
Edwards Lifesciences Quarterly Total Liabilities
(Millions of US $)
2023-03-31 $2,589
2022-12-31 $2,486
2022-09-30 $2,420
2022-06-30 $2,482
2022-03-31 $2,575
2021-12-31 $2,667
2021-09-30 $2,619
2021-06-30 $2,529
2021-03-31 $2,555
2020-12-31 $2,663
2020-09-30 $2,591
2020-06-30 $2,585
2020-03-31 $2,175
2019-12-31 $2,340
2019-09-30 $2,152
2019-06-30 $2,073
2019-03-31 $2,022
2018-12-31 $2,183
2018-09-30 $2,597
2018-06-30 $2,522
2018-03-31 $2,579
2017-12-31 $2,710
2017-09-30 $2,326
2017-06-30 $2,199
2017-03-31 $2,038
2016-12-31 $1,891
2016-09-30 $1,647
2016-06-30 $1,580
2016-03-31 $1,555
2015-12-31 $1,553
2015-09-30 $1,455
2015-06-30 $1,320
2015-03-31 $1,275
2014-12-31 $1,332
2014-09-30 $1,307
2014-06-30 $1,412
2014-03-31 $1,311
2013-12-31 $1,166
2013-09-30 $1,093
2013-06-30 $760
2013-03-31 $705
2012-12-31 $742
2012-09-30 $660
2012-06-30 $641
2012-03-31 $614
2011-12-31 $643
2011-09-30 $628
2011-06-30 $617
2011-03-31 $573
2010-12-31 $459
2010-09-30 $492
2010-06-30 $524
2010-03-31 $453
2009-12-31 $458
2009-09-30 $512
2009-06-30 $462
2009-03-31 $416
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $51.668B $5.382B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $200.336B 24.71
Alcon (ALC) Switzerland $38.531B 34.94
STERIS (STE) Ireland $19.969B 24.66
Fresenius Medical Care AG KGaA (FMS) Germany $12.634B 14.07
Penumbra (PEN) United States $12.021B 766.44
Teleflex (TFX) United States $10.964B 17.62
Globus Medical (GMED) United States $5.519B 25.23
Glaukos (GKOS) United States $2.836B 0.00
Integer Holdings (ITGR) United States $2.750B 20.81
Paragon 28 (FNA) United States $1.497B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.144B 14.77
Nevro (NVRO) United States $0.982B 0.00
Artivion (AORT) United States $0.604B 369.25